A strong and growing portfolio
We are an integrated biotechnology company dedicated to rare diseases. Our research and product portfolio is primarily focused on haemophilia, inflammation and genetic and metabolic diseases.We also market and make available across Europe, the Middle East, North Africa and Russia a portfolio of specialty and rare disease products for partner companies. In addition, we manufacture the drug substance for the haemophilia treatment ReFacto AF/Xyntha® for the global market.
These are proprietary products or products where
Sobi has global or regional rights.
Partner Products comprise about 40 products which are commercialized on behalf of specialty and rare disease partner companies.
Sobi is the global supplier of the drug substance for ReFacto AF®/XYNTHA®, a drug sold by Pfizer for the treatment of hemophilia A.
Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm, SwedenPhone: +46 8 697 20 00
© 2013 Swedish Orphan Biovitrum AB (publ) – All rights reserved
Společnost SOBI již dále nenese odpovědnost za obsah ani funkčnost internetových stránek jiných subjektů.
Přejete si opustit stránky?